Company news

Nuwellis, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024

April 29, 2024

Nuwellis Announces Closing of $2.7 Million Public Offering

April 29, 2024

Nuwellis Announces Pricing of $2.7 Million Public Offering

April 25, 2024

Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

April 8, 2024

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

March 4, 2024

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 19, 2024

Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

January 3, 2024

Nuwellis, Inc. Announces Third Quarter 2023 Financial Results

November 6, 2023

Nuwellis Announces Board of Directors Transition

October 31, 2023

Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023

October 17, 2023

Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

October 12, 2023

Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption

October 9, 2023

Nuwellis, Inc. Announces Second Quarter 2023 Financial Results

August 7, 2023

Nuwellis Announces Plan for CFO Transition

August 7, 2023

Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023

July 17, 2023

Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.

June 19, 2023

Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors

June 4, 2023

Nuwellis, Inc. Announces First Quarter 2023 Financial Results

May 8, 2023

Nuwellis, Inc. To Announce First Quarter 2023 Financial Results on May 9, 2023

April 17, 2023

Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics

March 20, 2023

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

February 6, 2023

Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

January 8, 2023

Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer

January 4, 2023

Nuwellis, Inc. Announces Passage of Warrant Proposal

January 3, 2023

Nuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements

December 26, 2022

Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex

December 12, 2022

Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

December 7, 2022

Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

November 29, 2022

Nuwellis, Inc. Reports Third Quarter 2022 Financial Results

November 7, 2022

Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates

November 2, 2022

Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022

October 18, 2022

Nuwellis Announces Appointment of Chief Financial Officer

October 18, 2022

Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

October 17, 2022

Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering

October 13, 2022

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting

October 2, 2022

Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

September 26, 2022

Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

August 30, 2022

Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 18, 2022

Nuwellis, Inc. Announces Second Quarter 2022 Financial Results

August 8, 2022

Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

July 25, 2022

Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022

July 13, 2022

Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy

July 11, 2022

Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF

June 28, 2022

Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas

June 13, 2022

Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

May 16, 2022

Nuwellis, Inc. Announces First Quarter 2022 Financial Results

May 9, 2022

Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting

May 8, 2022

Nuwellis, Inc. To Announce First Quarter 2022 Financial Results on May 10, 2022

April 11, 2022

Nuwellis Announces IRB Approval to Begin Its REVERSE-HF Clinical Study

March 14, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 26 decks. Every deck is listed under its year.